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Background and Purpose—Atherosclerotic middle cerebral arteries are frequent sites of thrombosis, leading to stroke.
Previous studies have suggested a role for Chlamydia pneumoniae in the pathogenesis of atherosclerosis. However, the
presence of this pathogen in atherosclerotic middle cerebral arteries has heretofore not been documented. In the present
study, we analyzed atheromatous plaques from middle cerebral arteries for the presence of C pneumoniae.
Methods—Atherosclerotic middle cerebral arteries from 15 cadavers who died of natural causes and corresponding
nonatherosclerotic arteries from 4 otherwise healthy trauma victims were examined. Assays for C pneumoniae DNA
were carried out by nested polymerase chain reaction (nPCR) specific for the C pneumoniae ompA gene. The presence
of the bacterium was assessed by transmission electron microscopy.
Results—Five of the 15 atherosclerotic arterial samples and none of the control tissues were positive for C pneumoniae
by nPCR. Particles similar in morphology and size to C pneumoniae elementary bodies were detected by transmission
electron microscopy in 4 of the 5 nPCR-positive atherosclerotic samples.
Conclusions—The demonstration of C pneumoniae in atherosclerotic middle cerebral arteries is consistent with the
hypothesis that this bacterium is involved in acute and chronic cerebrovascular diseases. (Stroke. 2001;32:1973-1978.)
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Atherosclerosis is a multifactorial disease. The variousexplanations of the pathogenic process include chronic
infection with certain pathogens. The microorganism most
strongly implicated in the initiation/progression of atheroscle-
rosis is the obligate intracellular bacterium Chlamydia pneu-
moniae, which commonly causes respiratory infections.
Evidence for a possible link between C pneumoniae
infection and atherosclerosis at different vascular sites has
come from seroepidemiology, analysis by polymerase chain
reaction (PCR), electron microscopy, in situ hybridization,
immunohistochemistry, culturing, and animal models.1– 4
However, the association of chronic C pneumoniae infection
and cerebrovascular diseases has not been well investigated.
Case-control studies revealed that specific anti–C pneu-
moniae antibody levels were significantly higher in patients
with cerebrovascular disease than in control patients,5–7
and a follow-up study indicated that high antibody titers to
C pneumoniae were associated with an increased risk of
future stroke.8 Immunoreactivity to C pneumoniae–specific
antigen was recently demonstrated in a low percentage of
anterior and posterior cerebral arteries but not in middle
cerebral arteries.9
The middle cerebral artery and internal carotid artery are
frequent sites of thrombosis leading to stroke. One of the
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most important factors in the development of local thrombo-
sis is the underlying atherosclerosis of the vessel wall. In the
present study, we used nested PCR (nPCR) and transmission
electron microscopy (TEM) to examine samples of middle
cerebral arteries with atheromatous plaques and also samples
of nondiseased vessels for the presence of C pneumoniae.
Subjects and Methods
Atherosclerotic samples of middle cerebral arteries were obtained
from 15 consecutively autopsied subjects. Samples were collected
within 24 hours after death with the use of sterile instruments. Half
of each sample was frozen at 270°C for nPCR analysis; the other
half was fixed in 3% glutaraldehyde for TEM and histology. For
control tissues, samples of 4 nonatherosclerotic middle cerebral
arteries were collected from trauma victims who died (at ages 31 to
40) during the study period. Histological assessment of the vessel
samples from the 15 patients indicated moderate or severe athero-
sclerotic stenosis. The control samples from the trauma victims were
assessed as histologically normal. The study was approved by an
institutional review committee.
DNA was extracted from frozen samples with the High Pure PCR
Template Preparation Kit (Boehringer-Roche) according to the
manufacturer’s instructions. Samples from cases or controls were
tested in a blinded fashion for C pneumoniae DNA with a GeneApm
2400 PCR system (Perkin-Elmer) with the use of nPCR primer pairs
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specific for the C pneumoniae ompA gene,10 resulting in a 206-bp
nPCR fragment. The presence of intact DNA was tested for each
sample with the use of primers specific for the human b-actin gene.
DNA extracted from the lysate of C pneumoniae (strain TWAR)–
infected McCoy cells (both from American Type Culture Collection)
was used as a positive control. The negative control was sterile
distilled water subjected to the same extraction procedure as used for
the tissue samples. For every set of 5 tested samples, nPCR including
the negative control template was carried out. Strict precautions were
taken to avoid contamination during DNA extraction and the
preparation of the reaction mixture. Problems and limitations of PCR
were considered as suggested.11,12
DNA samples amplified by the C pneumoniae primers were
sequenced with the ABI Prism DNA Sequencing Ready Detection
Kit (Perkin-Elmer). Fixed samples of the 5 C pneumoniae nPCR-
positive arteries and also the 5 C pneumoniae nPCR-negative
samples were postfixed in OsO4 and embedded in Epon. Thin
sections stained with uranyl acetate and lead citrate were examined
by TEM. McCoy cells infected with C pneumoniae were treated
similarly for morphological comparison.
Results
The patient characteristics reviewed from the autopsy records
and the nPCR results are listed in the Table. C pneumoniae
DNA was amplified in 5 of the 15 atherosclerotic samples, as
demonstrated by a 206-bp DNA fragment visualized by
agarose gel electrophoresis, whereas none of the 4 arterial
samples from healthy trauma victims were nPCR positive
(Figure 1). Sequencing of nPCR fragments from 2 of the 5
atherosclerotic samples revealed identity to the ompA se-
quences obtained from the National Center for Biotechnology
Information (NCBI) database (which can be accessed online
at http://www.ncbi.nlm.nih.gov). Three of the 5 nPCR-
positive cases had symptomatic cerebrovascular disease (ce-
rebral infarct), whereas only 2 of the 10 nPCR-negative cases
had symptomatic cerebrovascular disease. The direct cause of
death was related to infectious respiratory diseases in 9 of the
15 cases; there was uniform distribution among nPCR-
positive and -negative individuals (Table).
TEM of intimal plaques showed structures resembling
C pneumoniae elementary bodies in 4 of the 5 nPCR-positive
atherosclerotic arterial samples. These structures had a pear-
shaped appearance with a dense core (Figures 2A and 2B) and
were ’0.3 mm in diameter, ie, similar to the size of the
elementary bodies detected in control infected tissue culture
cells (Figure 2C). None of the 5 nPCR-negative atheroscle-
rotic samples examined by TEM exhibited C pneumoniae–
like structures.
Patient Characteristics Reviewed From Autopsy Records
Patient Sex Age, y C pneumoniae PCR Organ Manifestations of AT Diseases Other Than AT Cause of Death
1 M 95 1 CI, IHD, severe in aorta Bilateral chronic pyelonephritis Pneumonia
2 M 85 1 CI, severe in aorta, renovascular hypertension Duodenal ulcer Pneumonia
3 M 83 1 CI, IHD, severe in aorta Cirrhosis of liver Cardiac failure
4 F 76 1 IHD, severe in aorta and cerebral arteries Essential hypertension Sepsis
5 M 78 1 Mild in aorta and cerebral vessels Chronic lymphoid leukemia Purulent bronchiolitis
6 M 73 2 IHD, severe in aorta, gangrene of legs Bilateral chronic pyelonephritis Pneumonia
7 M 84 2 IHD, mild in aorta and cerebral arteries Essential hypertension Pneumonia
8 M 73 2 CI, IHD, moderate in aorta Essential hypertension Pneumonia
9 F 92 2 CI, IHD, atherosclerotic aneurysm in aorta Bilateral chronic pyelonephritis AMI
10 F 85 2 IHD, severe in aorta and moderate in cerebral
vessels, mesenteric superior artery
thrombosis
Essential hypertension Small bowel infarction
11 F 90 2 IHD, severe in aorta and cerebral vessels Perforated gastric ulcer Peritonitis
12 M 70 2 IHD, severe in aorta and cerebral vessels Diabetes, essential
hypertension
Pneumonia
13 M 66 2 Moderate in aorta and cerebral vessels Diabetes Bilateral acute pyelonephritis
14 M 71 2 IHD, severe in aorta and cerebral vessels Disseminated lung cancer Pneumonia
15 M 59 2 IHD, severe in aorta and cerebral vessels,
gangrene of leg
Hypopharynx cancer Pneumonia
AT indicates atherosclerosis; M, male; F, female; CI, cerebral infarct; IHD, ischemic heart disease (critical stenoses in coronaries with or without microscopic foci
of myocardial fibrosis and/or with or without myocardial scar); and AMI, acute myocardial infarction.
Figure 1. nPCR amplification of C pneumoniae ompA gene.
Lanes are as follows: 1 to 5, nPCR-positive atherosclerotic sam-
ples (206-bp fragments); 6, nPCR-negative sample; 7, negative
control; and 8, positive control. M indicates molecular size
marker (100-bp DNA ladder, Sigma).
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Discussion
C pneumoniae has several features that may lead to the
chronic infection of vessel walls and ultimately to atheroscle-
rosis with local thrombosis: the bacterium replicates in vitro
in endothelial and smooth muscle cells and macrophages,
induces the expression of adhesion molecules, elevates the
levels of platelet adhesion and procoagulant activity in
endothelial cells, and induces the production of cytokines
such as tumor necrosis factor-a, interleukin-1b, and
interleukin-6 in monocytes.13–16
C pneumoniae has been detected in atherosclerotic tissues
at different sites of the vascular system, including the carotid
and coronary arteries, the aortic valves, the aorta, and arteries
in the lower extremities. A summary of the results from 23
studies indicated that C pneumoniae was detected in 52%
(257 of 497) of diseased arteries and in 5% of control vessels
by immunohistochemistry or PCR.3 A recent study on the
prevalence of C pneumoniae antigens at multiple locations in
the arterial system within the same individual demonstrated a
high prevalence of immunoreactivity in the abdominal aorta,
iliac arteries, and coronary arteries and a low prevalence in
cerebral anterior and posterior arteries but no immunoreac-
tivity in samples of middle cerebral arteries.9 We detected the
presence of C pneumoniae DNA in 33% of the diseased
middle cerebral arterial samples by nPCR. A review of the
autopsy records revealed cerebral infarct in 3 of the 5
nPCR-positive cases, in contrast with only 2 of the 10
nPCR-negative cases. However, the small number of cases
did not permit a statistical comparison. A further limitation of
the present study is that the detectability of C pneumoniae
DNA in the cerebrovascular vessels might be related to age.
Because of the younger age of the control individuals and the
small numbers of nPCR-positive and -negative cases, statis-
tical comparison is not helpful, and this possibility cannot be
excluded. The present study has demonstrated the presence of
C pneumoniae DNA in some atherosclerotic samples from
middle cerebral arteries, but further studies appear desirable
to test for the presence of this organism in these vessels in
relation to age and the occurrence of symptomatic cerebro-
vascular diseases. Because there was no difference in the
incidence of respiratory diseases as the direct cause of death
among the nPCR-positive and -negative cases, it is improb-
able that C pneumoniae nPCR positivity was secondary to the
infectious diseases, which are rather considered to be
terminal-stage diseases that developed a few days before
death.
A commercial kit for the molecular detection of C pneu-
moniae is not available, but the considerations applied in our
work suggest that our PCR assay is appropriate.10–12
The detection of pear-shaped structures in C pneumoniae
nPCR-positive atherosclerotic samples by TEM suggests that
not only was bacterial DNA present but that the complete
pathogen was also present in the intimal plaque. A striking
aggregation of dense particles indicates an intracellular accu-
mulation of these structures. The additional presence of this
microorganism extracellularly suggests either spontaneous
autolysis of the cells followed by bacterial flow into the
extracellular matrix or the accumulation of these pathogens
outside the cell during a certain stage of their life cycle.
C pneumoniae organisms were earlier found by electron
microscopy in cells and interstitially in atherosclerotic lesions
of the aorta or carotid or coronary arteries but not in the
adjacent nonatherosclerotic tissue.17
The middle cerebral arteries are important sites of cerebral
thrombosis. The presence of C pneumoniae in the atheroma-
tous plaques of the middle cerebral artery does not necessar-
ily mean that the organism is a causative agent of the disease;
it rather raises the possibility of a role for this bacterium in the
pathogenic process. Such a role would point to the value of
antibiotic treatment as a means of attenuating cerebrovascular
diseases relating to C pneumoniae. Tests on a larger number
of cases and age- and sex-matched controls appear warranted,
extending to the C pneumoniae serostatus and the presence of
C pneumoniae DNA and antigens in vessels other than
middle cerebral arteries in the same subjects.
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Editorial Comment
Chlamydia pneumoniae: In Your Heart and on Your Mind
Infections have long been recognized as causes of cerebro-
vascular disease. Infectious endocarditis, meningovascular
syphilis, and varicella zoster virus–associated vasculitis are
rare but well-known infectious syndromes of stroke. In the
past decade, interest in the role of more common pathogens in
the pathophysiology of atherosclerosis and stroke has grown.
The best-studied of these infections is Chlamydia pneu-
moniae, but there is a growing body of literature implicating
other organisms, including cytomegalovirus, Helicobacter
pylori, and the multitude of bacteria that participate in
periodontitis.
It is now widely believed that atherosclerosis is predomi-
nantly an inflammatory condition produced by a “response to
injury.”1 A number of toxic stimuli can lead to endothelial
injury, resulting in a cascade of events, culminating in smooth
muscle cell proliferation and fibrous plaque formation. Oxi-
dized LDL is a well-recognized cause of this endothelial
injury, but homocysteine, toxic constituents of cigarette
smoke, and high shear force have also been implicated.
Infectious agents are hypothesized to be one more potential
source of injury.
Since the original observations in 1988 that the prevalence
of antibodies directed against C pneumoniae is higher among
those with coronary artery disease than among controls,2 a
number of retrospective and prospective epidemiological
studies have found an association of serological evidence of
C pneumoniae infection and coronary disease risk. A smaller
number of studies have found similar associations for risk of
ischemic stroke,3–6 though not all studies have been positive.7
The conclusions drawn from these studies, however, have
been limited by methodological considerations, including the
heterogeneity of stroke subtypes enrolled and the absence of
well-standardized tests for C pneumoniae. Although some
data suggest that specific antibody isotypes, such as immu-
noglobulin A antibodies, may be more specific for the chronic
infection thought to be associated with atherosclerotic dis-
ease,3,6 this conjecture has not yet been validated. More
recent efforts using PCR of peripheral blood mononuclear
cells in larger populations may help resolve these epidemio-
logical issues, although methodological concerns plague
these studies as well.
Ultimately, however, because analytic observational stud-
ies cannot provide proof that infection with C pneumoniae
causes atherosclerosis, investigators have relied on parallel
areas of clinical and basic investigation, including pathology,
in vitro and animal models, and clinical trials. The article by
Virok et al addresses the pathology and thus the biological
plausibility of the role of infection in cerebrovascular disease.
The authors used nested PCR to assess the presence of C
pneumoniae infection in middle cerebral arteries (MCAs)
taken at autopsy from 15 individuals with atherosclerosis of
the MCA and 4 healthy young individuals who died of
traumatic causes. Histologically, the case subjects all had
moderate or severe MCA atherosclerosis, while the MCA was
normal in all the control subjects. Five of the 15 case
specimens showed evidence of C pneumoniae DNA, whereas
none of the control samples did. Moreover, 3 of the 5
polymerase chain reaction (PCR)-positive cases (60%) had
symptomatic disease, whereas only 2 of the 10 PCR-negative
cases (20%) were symptomatic. Electron microscopy, fur-
thermore, demonstrated presence of C pneumoniae in 4 of 5
of the PCR-positive specimens.
While this study is limited by small numbers, it nonetheless
offers evidence that C pneumoniae can be found in cerebral
blood vessels. Because the controls selected were relatively
young, however, it is possible that the presence of the
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organism simply reflects age; it would have been ideal to
have had age-matched controls without atherosclerosis. Still,
the organism appears to have been found more often in the
atherosclerotic cerebral vessels.
Discovery of C pneumoniae DNA by PCR in tissue from
the MCA is not surprising. Several studies have found
evidence of C pneumoniae in arterial tissue taken from sites
throughout the body, including the coronary arteries,8 aorta9
and femoral10 arteries. Closer to the brain, C pneumoniae has
been identified using PCR and immunohistochemical tech-
niques in carotid atherosclerotic tissue taken from endarter-
ectomy specimens. The organism, notoriously difficult to
culture, has also been cultured from the carotid artery.11 A
1997 review12 of studies of C pneumoniae in atherosclerotic
tissue found that 257 of 495 samples of atheromatous tissue
(52%) were positive for C pneumonia, while only 6 of 118
nonatheromatous specimens (5%) were positive. A more
recent autopsy study13 sampled 33 arterial sites throughout
the body of each of 24 elderly individuals and found C
pneumoniae immunostaining in at least one artery in all
subjects. Almost all arteries were affected in at least some
individuals, although the prevalence was greatest in the
abdominal aorta, iliac arteries, and coronary arteries. Impor-
tantly, the prevalence was highest at sites of greatest luminal
stenosis, and in sites typically affected clinically. The organ-
ism was found in only 2% of all large cerebral vessels in that
study, however, compared with 33% of coronary vessels, and
not in any of the MCA specimens. The present study is thus
the first to find C pneumoniae in MCA tissue. It is of interest
that the organism was found so much more commonly in the
MCA tissue in the study by Virok et al, but this may simply
reflect the different patient population, which in their sample
included 15 patients with moderate or severe MCA stenosis.
Of course, the presence of C pneumoniae in arterial tissue
cannot itself establish this, or any other organism, as a
causative agent in atherosclerosis. Lipid-rich atherosclerotic
tissue may simply be an attractive resting ground for the
organisms, or they may be brought in by circulating macro-
phages entering the developing plaque. C pneumoniae, ac-
cording to this critique, is simply an “innocent bystander,”
and not involved directly in the pathogenic process. A small
but growing body of experimental and other animal evidence
is available to support the pathogenic role of C pneumoniae in
atherosclerosis, however. The presence of chlamydial lipo-
polysaccharide, for example, facilitates conversion of macro-
phages to foam cells and increases oxidative metabolism of
LDL, potentially damaging endothelium.14 C pneumoniae has
also been shown in vitro to induce human peripheral blood
monocytes to secrete proinflammatory cytokines known to
participate in the atherosclerotic process.1,15 In experimental
models, rabbits inoculated with C pneumoniae develop ath-
erosclerotic lesions while controls do not,16 and azithromycin,
a macrolide antibiotic active against chlamydiae, retards this
process.17
There is also evidence to suggest that some of the adverse
effects of infections on atherosclerosis could be caused
indirectly by immunological mechanisms, without the persis-
tence of organism itself in the vessel wall—what has been
called a “hit and run” effect.18 In rats undergoing arterial
balloon injury and infected with rat cytomegalovirus, for
example, arterial wall thickening progresses even after infec-
tion is completed and cytomegalovirus DNA is no longer
detectable in the vessel.19
Currently, several large-scale clinical trials are ongoing
among coronary disease patients to assess whether antibiotic
therapy can prevent recurrent events. Atherosclerosis, how-
ever, has several logically distinct, if continuous, phases,
including atherogenesis, progression, and plaque rupture, the
most common precipitant of an acute event. Different mech-
anisms may be operative in each of these phases. A trial
directed at reducing clinical events, therefore, even if nega-
tive, cannot prove that infectious agents are not involved in
the earlier processes of atherogenesis or progression.
No clinical trials in stroke have yet been initiated. It is
important to remember, however, that while the term “brain
attack” has heuristic value, a stroke is not simply a “heart
attack” of the brain. Again, even if negative, trials in heart
disease cannot definitively answer the question of the asso-
ciation of C pneumoniae and stroke. The etiologies of stroke
are more heterogeneous than those of coronary artery disease,
and it is possible that there are differential effects on the two.
Recent data from the National Health and Nutrition Exami-
nation Surveys, for instance, suggest an association of peri-
odontal disease with stroke but not heart disease.20,21 The
study by Virok et al, then, is important in being the first to
focus on the presence of this organism in the brain’s vessels
and thus in its recognition that research in stroke should begin
with an investigation of the brain’s arteries, and not simply
those elsewhere in the body. Further studies of the prevalence
of this organism in brain arteries and its clinical consequences
are needed.
Mitchell S. Elkind, MD, Guest Editor
Department of Neurology
Columbia University
New York, New York
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